Skip to content

Efficacy of single-session focused extracorporeal shockwave therapy in patients with moderate-degree carpal tunnel syndrome versus steroid injection therapy A single-blind randomized controlled trial

Efficacy of single-session focused extracorporeal shockwave therapy in patients with moderate-degree carpal tunnel syndrome versus steroid injection therapy A single-blind randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240704004
Enrollment
36
Registered
2024-07-04
Start date
2021-03-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with electrophysiological evidence of moderate-degree carpal tunnel syndrome Carpal tunnel syndrome, Focused extracorporeal shockwave therapy, Steroid injection

Interventions

received treatment via an injection of 10 milligrams of Triamcinolone Acetonide (TA) in 1 milliliter of solution, administered at a 45-degree angle to the medial side of the flexor retinaculum using a
Triamcinolone Acetonide (TA),fESWT

Sponsors

Faculty of Medicine, Srinakharinwirot University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria 1) Symptoms include numbness or pain in the palm of the hand, plus positive findings from Phalen's, Tinel's and Median compression's test 2) Patients diagnosed with moderate carpal tunnel syndrome by electrodiagnosis show a reduction in conduction velocity of both sensory and motor fibers of the median nerve and/or a reduction in SNAP amplitudes to lower than 50% of normal values. [4] 3) The patient is 18 years old and over. And 4) A new patient who has not been treated with a steroid injection or other treatments, such as ultrasound therapy.

Exclusion criteria

Exclusion criteria: 1) History of physical therapy treatment in the previous six months 2) Contraindications for fESWT such as pacemarker implantation, pregnancy 3) Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale (VAS) for pain 0,4,8,12 weeks VAS

Secondary

MeasureTime frame
Boston Carpal Tunnel Questionnaire Symptom Severity Scale 0,4,8,12 weeks Boston Carpal Tunnel Questionnaire Symptom Severity Scale

Countries

Thailand

Contacts

Public ContactWoraphon Aramrussameekul

Faculty of Medicine, Srinakharinwirot University

voraphol@g.swu.ac.th0816894343

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026